Organisation paid for research Program year 2024 Source: CMS Open Payments

Virginia Research Center LLC

Neither a doctor nor a teaching hospital

Research payments

$16,936,818

521 payments

Through program year 2024, Virginia Research Center LLC is reported as receiving $16,936,818 in research payments, across 521 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $619,100 26
2023 Research $2,764,108 127
2022 Research $6,475,914 103
2021 Research $4,438,734 105
2020 Research $2,069,816 84
2019 Research $569,146 76

Breakdown

Who paid Research payments · program years 2019–2024
  1. Pfizer Inc. $16,500,006 440 payments
  2. AbbVie, Inc. $285,761 65 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $95,576 6 payments
  4. AstraZeneca Pharmaceuticals LP $33,942 5 payments
  5. Eli Lilly and Company $11,783 2 payments
  6. GlaxoSmithKline, LLC. $9,750 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $6,057,032 102 payments
  2. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $4,033,837 76 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,213,871 51 payments
  4. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $2,038,046 41 payments
  5. A Master Phase 123 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b2 Rna Based Vaccine Candidates in Healthy Children $608,436 20 payments
  6. A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $408,398 41 payments
  7. An Interventional Randomized Activecontrolled Phase 23 Study to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b Rnabased Vaccine Candidates As A Booster Dose in Covid19 Vaccineexperienced Healthy Individuals $397,820 21 payments
  8. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $359,644 58 payments
  9. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $330,381 14 payments
  10. M16-100 $168,647 32 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record